BofA: Investors pour into bonds, pull back from crypto
In a recent transaction, Robin Swartz, the Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), sold a portion of her holdings in the company. The stock has experienced significant pressure lately, trading near its 52-week low of $5.03, according to InvestingPro data. The sale involved 3,087 shares of common stock at an average price of $5.09 per share, totaling approximately $15,712. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.23. Following this sale, Swartz retains ownership of 109,241 shares in the company. Despite recent market pressure, Voyager maintains a strong financial position with more cash than debt and liquid assets exceeding short-term obligations. InvestingPro subscribers have access to 10 additional key insights about VYGR's financial health and growth prospects.
In other recent news, Voyager Therapeutics has been met with positive outlooks from multiple analyst firms. The company received a Buy rating from Citi, and an Outperform rating was reiterated by Oppenheimer. Both firms highlighted Voyager Therapeutics' strong financial position and the potential of its gene therapy pipeline. The company's most recent earnings report revealed $24.6 million in collaboration revenue and operational expenses of $38.4 million, with a substantial cash reserve of $345.4 million, projected to fund operations into 2027.
Voyager Therapeutics is making significant strides in the field of neurological disease treatments. The company is expected to submit Investigational New Drug applications for its SOD1 ALS gene therapy and two partnered gene therapies for Friedreich’s ataxia and Parkinson’s disease in 2025. Moreover, the company's anti-tau antibody, VY7523, is currently undergoing a Phase 1a trial, with data expected in the first half of 2025.
The results of the Phase 2a TOGETHER study of bepranemab in early Alzheimer's disease have been viewed as a positive indicator for VY7523's potential by Oppenheimer. Voyager Therapeutics has completed enrollment for VY7523's single ascending dose trial and plans to report initial data in the first half of 2025. A multiple ascending dose trial for early Alzheimer's patients is set for 2025, with tau PET imaging data expected by the end of 2026. These recent developments underline Voyager Therapeutics' commitment to advancing treatments for neurological diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.